These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12890902)

  • 1. [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate].
    Minami S; Hattori R; Matsuda A
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):161-78. PubMed ID: 12890902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
    Fukuda H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of pazufloxacin (PZFX) against clinical isolates from infectious enteritis].
    Fukuyama M; Oonaka K; Hara M; Imagawa Y
    Kansenshogaku Zasshi; 1996 Jan; 70(1):51-9. PubMed ID: 8822053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazufloxacin Toyama Chemical Co.
    Johnson AP
    Curr Opin Investig Drugs; 2000 Sep; 1(1):52-7. PubMed ID: 11249595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
    Nagasawa M; Nakamura S; Miyazaki M; Nojima Y; Hayakawa H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):259-69. PubMed ID: 12199110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Attenuation of arbekacin-induced nephrotoxicity in rats by pazufloxacin mesilate].
    Kizawa K; Miyazaki M; Nagasawa M; Ogake N; Nagai A; Sanzen T; Kawamura Y
    Jpn J Antibiot; 2003 Feb; 56(1):44-54. PubMed ID: 12723398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis].
    Sagara H; Yoshikawa K; Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Matsumoto F; Imai T; Sakurai I; Takahashi T; Mori M; Mizuno Y; Katoh K; Hosoda S; Bamba T; Saito M
    Kansenshogaku Zasshi; 1996 Jan; 70(1):60-72. PubMed ID: 8822054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pazufloxacin mesilate, a new quinolone antibacterial agent, for intravenous use on QT interval].
    Fukuda H; Morita Y; Shiotani N; Mizuo M; Komae N
    Jpn J Antibiot; 2004 Aug; 57(4):404-12. PubMed ID: 15535041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats.
    Hayakawa H; Takagi K; Takano YF; Kawamura Y; Tsuji A
    J Pharm Pharmacol; 2002 Sep; 54(9):1229-36. PubMed ID: 12356277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus].
    Maekawa M; Takahashi K; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of target attainment rate of pazufloxacin mesilate using Monte Carlo simulation method].
    Abe N; Fukuda S; Nakamura A; Taguchi Y; Matsuo S
    Jpn J Antibiot; 2010 Aug; 63(4):319-25. PubMed ID: 21298865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)].
    Yanagisawa C; Hanaki H; Oishi T; Uehara K; Yamaguchi Y; Matui H; Sunakawa K
    Jpn J Antibiot; 2005 Feb; 58(1):11-6. PubMed ID: 15847221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antimicrobial agents using an experimental pulmonary superinfection model with Aspergillus fumigatus and Pseudomonas aeruginosain leukopenic mice.
    Mitsuyama J; Kizawa K; Minami S; Watanabe Y; Yamaguchi K
    J Infect Chemother; 2003 Jun; 9(2):144-50. PubMed ID: 12825113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver abscess that responded well to pazufloxacin therapy.
    Hamada Y; Imaizumi H; Kobayashi M; Sunakawa K; Saigenji K; Yago K
    J Infect Chemother; 2006 Feb; 12(1):42-6. PubMed ID: 16506089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections.
    Shinkawa A; Kimura H; Sakai M; Miyake H
    Drugs; 1995; 49 Suppl 2():401-2. PubMed ID: 8549377
    [No Abstract]   [Full Text] [Related]  

  • 18. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cefoperazone and azithromycin on the pharmacokinetics of pazufloxacin in rats.
    Lou S; Li W; Hu Q
    Eur J Drug Metab Pharmacokinet; 2007; 32(4):219-23. PubMed ID: 18348471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of an injectable new quinolone, pazufloxacin, against polymicrobial infections in the uterine endometritis model.
    Mikamo H; Kawazoe K; Sato Y; Tamaya T
    Chemotherapy; 1998; 44(2):99-102. PubMed ID: 9551239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.